Moral entrepreneurship, the power-knowledge nexus, and the Cochrane "crisis".


Journal

Journal of evaluation in clinical practice
ISSN: 1365-2753
Titre abrégé: J Eval Clin Pract
Pays: England
ID NLM: 9609066

Informations de publication

Date de publication:
10 2019
Historique:
received: 14 01 2019
revised: 18 02 2019
accepted: 19 02 2019
pubmed: 20 3 2019
medline: 26 6 2020
entrez: 20 3 2019
Statut: ppublish

Résumé

In 2018, a so-called crisis developed in the international network of systematic reviewers known as Cochrane. It was widely depicted in terms of two competing narratives-"bad behaviour" by one member of Cochrane's Governing Board and scientific and moral decline within Cochrane. Our goal was to distil insights on the structural issues underpinning the crisis, without taking a definitive position on the accuracy of either narrative. In this paper, we draw on (among other theories) Becker's notion of moral entrepreneurship and Foucault's conceptualisation of power to analyse the claims and counterclaims made by different parties. Our dataset consisted of publicly available materials (blogs, journal articles, newspaper articles) to end 2018, notably those relating to the expulsion of one Governing Board member. Both narratives include strong moral claims about the science of systematic review and the governance of scientific organizations. The expelled individual and his supporters defined good systematic reviews in terms of a particular kind of methodological rigour and elimination of bias, and good governance largely in terms of measures to achieve independence from industry influence. Most of Cochrane's Governing Board and their sympathizers evaluated systematic reviews according to a broader range of criteria, incorporating factors such as attention to relationships among reviewers and reflexivity and dialogue around scientific and other judgements. They viewed governance partly in terms of accountability to an external advisory group. Power-knowledge alignments in Cochrane have emerged from, and contributed to, a particular system of meaning which is now undergoing evolution and challenge. Polarizing Cochrane's "crisis" into two narratives, only one of which is true, is less fruitful than viewing it in terms of a duality consisting of tensions between the two positions, each of which has some validity. Having framed the conflict as primarily philosophical and political rather than methodological and procedural, we suggest how Cochrane and its supporters and critics might harness their tensions productively.

Sections du résumé

BACKGROUND
In 2018, a so-called crisis developed in the international network of systematic reviewers known as Cochrane. It was widely depicted in terms of two competing narratives-"bad behaviour" by one member of Cochrane's Governing Board and scientific and moral decline within Cochrane.
OBJECTIVE
Our goal was to distil insights on the structural issues underpinning the crisis, without taking a definitive position on the accuracy of either narrative.
APPROACH AND DATASET
In this paper, we draw on (among other theories) Becker's notion of moral entrepreneurship and Foucault's conceptualisation of power to analyse the claims and counterclaims made by different parties. Our dataset consisted of publicly available materials (blogs, journal articles, newspaper articles) to end 2018, notably those relating to the expulsion of one Governing Board member.
MAIN FINDINGS
Both narratives include strong moral claims about the science of systematic review and the governance of scientific organizations. The expelled individual and his supporters defined good systematic reviews in terms of a particular kind of methodological rigour and elimination of bias, and good governance largely in terms of measures to achieve independence from industry influence. Most of Cochrane's Governing Board and their sympathizers evaluated systematic reviews according to a broader range of criteria, incorporating factors such as attention to relationships among reviewers and reflexivity and dialogue around scientific and other judgements. They viewed governance partly in terms of accountability to an external advisory group. Power-knowledge alignments in Cochrane have emerged from, and contributed to, a particular system of meaning which is now undergoing evolution and challenge.
CONCLUSION
Polarizing Cochrane's "crisis" into two narratives, only one of which is true, is less fruitful than viewing it in terms of a duality consisting of tensions between the two positions, each of which has some validity. Having framed the conflict as primarily philosophical and political rather than methodological and procedural, we suggest how Cochrane and its supporters and critics might harness their tensions productively.

Identifiants

pubmed: 30887656
doi: 10.1111/jep.13124
pmc: PMC6952841
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

717-725

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust Senior Investigator Award to TG
ID : WT104830MA
Pays : International
Organisme : National Institute for Health Research Biomedical Research Centre grant to University of Oxford
ID : BRC-1215-20008
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2019 The Authors Journal of Evaluation in Clinical Practice Published by John Wiley & Sons Ltd.

Références

BMJ. 2018 Sep 24;362:k3694
pubmed: 30249615
J Clin Epidemiol. 2015 Jul;68(7):811-20
pubmed: 25748073
Eur J Clin Invest. 2019 Mar;49(3):e13058
pubmed: 30520025
BMJ Evid Based Med. 2019 Feb;24(1):1-4
pubmed: 30209151
BMC Med Ethics. 2015 Oct 12;16(1):69
pubmed: 26459219
Syst Rev. 2017 Aug 1;6(1):149
pubmed: 28764779
J Eval Clin Pract. 2018 Oct;24(5):930-938
pubmed: 30079500
BMJ. 2014 Jun 13;348:g3725
pubmed: 24927763
BMJ. 2012 Nov 01;345:e7031
pubmed: 23118303
BMJ Evid Based Med. 2018 Oct;23(5):165-168
pubmed: 30054374
J Eval Clin Pract. 2019 Oct;25(5):717-725
pubmed: 30887656
BMJ Qual Saf. 2018 Sep;27(9):710-717
pubmed: 29459365
Syst Rev. 2017 Feb 15;6(1):28
pubmed: 28196521
Eur J Clin Invest. 2013 May;43(5):469-75
pubmed: 23521369
J Med Ethics. 2004 Apr;30(2):171-5
pubmed: 15082812
Lancet. 2018 Sep 29;392(10153):1103-1104
pubmed: 30303072
BMC Med. 2018 Jun 20;16(1):95
pubmed: 29921272
Cochrane Database Syst Rev. 2018 May 09;5:CD009069
pubmed: 29740819
Lancet. 2012 Jul 21;380(9838):218
pubmed: 22817975
Eur J Clin Invest. 2018 Jun;48(6):e12931
pubmed: 29578574
BMJ. 2017 Jan 17;356:i6770
pubmed: 28096109

Auteurs

Trisha Greenhalgh (T)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Mustafa F Ozbilgin (MF)

Brunel Business School, Brunel University London, London, UK.

Barbara Prainsack (B)

Department of Political Science, University of Vienna, Wien, Austria.
Department of Global Health and Social Medicine, King's College London, London, UK.

Sara Shaw (S)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH